medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (5)


Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island

Francheville JW, Rankin R, Beck J, Hoare C, Materniak S, German G, Barrett L, Bunimov-Wall N, Smyth D

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 749-758
Archivo PDF: 185.24 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lee J, Conniff J, Kraus C, Schrager S. A brief clinical update on hepatitis C - The essentials. Wisc Med J 2015; 114: 263-9.

  2. Moorman AC, Gordon SC, Rupp LB, Spradling PR, Teshale EH, Lu M, Nerenz DR, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study. Clin Infect Dis 2013; 56: 40-50.

  3. O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134: 1764-76.

  4. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol and Hepatol 2010; 8: 280-8.e1.

  5. Morgan TR, Ghany MG, Kim H, Snow KK, Shiffman ML, De Santo JL, Lee WM, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.

  6. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of allcause mortality in patients with hepatitis C. Clin Gastroenterol and Hepatol 2011; 9: 509-16.e1.

  7. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis c and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

  8. MacParland SA, Bilodeau M, Grebely J, Bruneau J, Cooper C, Klein M, Sagan SM, et al. The 3rd Canadian Symposium on Hepatitis C Virus: Expanding care in the interferon-free era. Can J Gastroenterol and Hepatol 2014; 28: 481-7.

  9. Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: A descriptive study. CMAJ Open 2016; 4: E605- E614.

  10. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163: 215-23.

  11. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598-609.

  12. Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, Aitken C, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 2014; 60: 1861-70.

  13. Smyth DJ, Webster D, Barrett L, MacMillan M, McKnight L, Schweiger F. Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: A policy statement and implementation guideline. Can J Gastroenterol and Hepatol 2014; 28: 529-34.

  14. Statistics Canada. Census profile: Prince Edward Island, 2016 census. 2017. http://www12.statcan.gc.ca/census-recensement/ 2016/dp-pd/prof/index.cfm?Lang=E. Accessed June 13, 2017.

  15. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada, 2007: Final report. Public Health Agency of Canada 2007. Available at: http:// www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/model07- eng.pdf. Accessed November 16, 2016.

  16. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol and Hepatol 2015; 29: 19-34.

  17. De Ledinghen V, Vergniol J. Transient elastography (fibroscan). Gastroenterol Clin Biol 2008; 32: 58-67.

  18. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373: 2599-607.

  19. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373: 2608-17.

  20. Leroy V, Angus P, Bronowicki J, Dore GJ, Hezode C, Pianko S, Pol S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3). Hepatology 2016; 63: 1430-41.

  21. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlier‘e M, Sulkowski MS, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J Med 2014; 370: 1604-14.

  22. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, et al. Treatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. New Engl J Med 2014; 370: 1594-603.

  23. Dore G, Altice F, Litwin A, Dalgard O, Gane E, Shibolet O. CEDGE CO-STAR: Efficacy of grazoprevir/elbasvir fixed dose combination for 12 weeks in HCV-infected persons who inject drugs on opioid agonist therapy. Hepatology 2015; 62: 227A-228A.

  24. Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 2015; 63: 364-9.




2020     |     www.medigraphic.com